SCHEMBL2447423

SCHEMBL2447423

Cn1cc(-c2ccnc(Oc3ccc(F)c(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)c3)n2)cn1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 12/20 0.40
PDGFRB P09619 8/20 0.40
PDGFRA P16234 7/20 0.40
MET P08581 6/20 0.40
FLT3 P36888 4/20 0.40
KDR P35968 4/20 0.40
AXL P30530 4/20 0.38
KIT P10721 5/20 0.38
MKNK1 Q9BUB5 1/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
FGFR1 P11362 1/20 0.36
FGFR2 P21802 1/20 0.36
FGFR4 P22455 1/20 0.36
FGFR3 P22607 1/20 0.36
PDE10A Q9Y233 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2409748 0.89 CSF1R (0.39) CSF1RPDGFRBPDGFRAMETFLT3
SCHEMBL3490673 0.87 MAPT (0.39) METAXLMAPTL3MBTL1FGFR1
SCHEMBL2444261 0.84 CSF1R (0.50) CSF1RPDGFRBPDGFRAMETFLT3
SCHEMBL2456146 0.82 CSF1R (0.49) CSF1RPDGFRBPDGFRAMETFLT3
SCHEMBL2410533 0.82 CSF1R (0.51) CSF1RPDGFRBPDGFRAMETFLT3
SCHEMBL2419481 0.81 CSF1R (0.46) CSF1RPDGFRBPDGFRAMETFLT3
SCHEMBL2413707 0.79 KDR (0.45) CSF1RPDGFRBPDGFRAMETFLT3
SCHEMBL3494015 0.79 AXL (0.47) CSF1RPDGFRBPDGFRAMETFLT3
SCHEMBL2444168 0.79 CSF1R (0.54) CSF1RPDGFRBPDGFRAMETFLT3
SCHEMBL3491534 0.79 CSF1R (0.54) CSF1RPDGFRBPDGFRAMETFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2365752-B1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2014-09-24 EP disclosed
US-8486951-B2 Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2013-07-16 US disclosed
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-03-28 US disclosed
US-8278331-B2 N-acyl ureas exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2012-10-02 US disclosed
EP-2365752-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, Llc (US) 2011-09-21 EP disclosed
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2010-05-13 US disclosed
WO-2010051373-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB CSF1R 14/4885PDGFRB 3/4885PDGFRA 2/4885
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB CSF1R 9/4885PDGFRB 3/4885PDGFRA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.